BAFNA PHARMACEUTICALS LTD. - 532989 - Discrepancies In Financial Results.
As per BSE e-mail dated December 08, 2023, certified true copy of the resolution passed in the Board of Directors in their meeting held on November 09, 2023, along with the signed financials submitted on the date of Board meeting. BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Strikes /Lockouts / Disturbances
Commercial productions of the Company has been started from today i.e., Friday, December 08, 2023. BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Strikes /Lockouts / Disturbances
we hereby inform you that due to torrential rains/impact of "Michaung" cyclone, the Company''s manufacturing facilities in Chennai, Tamil Nadu, was totally flooded/waterlogged around the facilities, and the production activities have been disrupted from December 04, 2023. the Company is assessing the situation and simultaneously undertaking all the requisite actions like draining the water from the facilities, etc., to resume the operations of the facilities. BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Newspaper Publication
we have furnished herewith newspaper clippings of Un-audited Standalone Financial Results of the Company for the II quarter and half year ended September 30, 2023, which was approved by the Board in its meeting held on November 09, 2023, and published in the newspaper, namely in Makkal Kural (Tamil version) and Business Standard (English version) on Friday, November 10, 2023. BAFNA PHARMACEUTICALS LTD. - 532989 - Financial Results For The Quarter And Half Year Ended September 2023.
we wish to inform that at the meeting of the Board of Directors of the Company held on November 09, 2023, the results for the quarter ended September 30, 2023, duly reviewed and recommended by the Audit Committee, inter-alia, has been considered and approved by the Board of Directors of the Company. BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Approval Of Un-Audited Financial Results Of The Company For The II Quarter And Half Year Ended September 30, 2023, For The FY 2023-24.
We wish to inform that at the meeting of the Board of Directors of the Company held today i.e., November 09, 2023, Thursday, the results for the quarter and half-year ended on September 30, 2023, duly reviewed and recommended by the Audit Committee, inter-alia, has been considered and approved by the Board of Directors of the Company. In this regard, we enclose the following: BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Intimation Of Meeting Of Board Of Directors - Approval Of Q2 FY24 Financial Results.
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 ,inter alia, to consider and approve A meeting of Board of Directors of the Company is scheduled to be held on Thursday, November 09, 2023, inter-alia, to consider and approve the Un-Audited Standalone Financial Results of the Company for the second quarter of FY24 and half year ended September 30, 2023, together with the 'Limited Review Report' for the said period. BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018. BAFNA PHARMACEUTICALS LTD. - 532989 - Submission Of Certificate By RTA In Compliance Of Regulation 74(5) Of SEBI (Depository & Participants) Regulations, 2018, For The Quarter Ended September 30, 2023.
Pursuant to regulation 74(5) of SEBI(Depositories and Participants) Regulations, 2018, we enclosed herewith a certificate dated October 06, 2023, received from Cameo Corporate Services Limited, RTA of the Company, confirming dematerialization of share certificate during the quarter ended September 30, 2023. BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints - Quarter Ended September 30, 2023.
Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Statement of Investor Complaints for the quarter ended September 30, 2023.